BOTHELL, Wash., March 1, 2011 /PRNewswire/ -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated at Overlake Hospital Medical Center in Bellevue and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths. Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion.Warfarin is prescribed to 2 million patients in the U.S. annually and approximately 20 million Americans use the drug in total. Warfarin is difficult to dose as patients respond to it differently according to their genetic makeup -- too much warfarin can result in severe bleeding, and too little can cause clot formation and increased risk of stroke. In the past, warfarin dosing relied on trial-and-error, which exposed patients to serious medical risks. Warfarin is the second most frequent cause of drug-related emergency room visits.
"Safeguarding the health of our citizens is always a top priority of government," said Rogers Weed, Director of the Washington State Department of Commerce. "The WARFARIN Study aims to demonstrate that using genetic testing for warfarin dosing can improve patients' overall health, save lives and lower healthcare costs here in Washington as well as nationwide. As a leader in advancing genetically-based medical practice, Washington is proud that a local company and one of our state's premier hospitals are taking the lead in th
|SOURCE Iverson Genetic Diagnostics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved